- Home
- WRAP vs CNTB Comparison
WRAP vs CNTB Comparison
Compare WRAP & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRAP | CNTB |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.8M | 135.7M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WRAP | CNTB |
|---|---|---|
| Price | $1.30 | $2.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | ★ 183.7K | 145.1K |
| Earning Date | 05-13-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,672,000.00 | $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $1.20 | $0.73 |
| 52 Week High | $3.23 | $3.82 |
Technical Indicators
Market Signals| Indicator | WRAP | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 35.53 | 44.75 |
| Support Level | $1.26 | $2.30 |
| Resistance Level | $1.66 | $2.67 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 10.02 | 31.44 |
Price Performance
Historical ComparisonAbout WRAP Wrap Technologies Inc.
Wrap Technologies Inc is a public safety technology and services company that delivers safe and effective policing solutions to law enforcement and security personnel. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.